Countdown 01 days | Huiju pharmaceutical thousand people talk about new drug development

The research and development of new drugs is a complex process, and the listing of a new drug requires joint efforts of multiple resources In the past, in the process of R & D, we usually concentrated our resources to make up our own shortcomings to achieve a higher new drug output rate; however, the current development of biomedical science and technology is changing with each passing day, and business models emerge in endlessly, so the "single fight" model of centralized resources to make up the shortcomings is difficult to adapt to the environment At present, the technological innovation of new drug research and development, the increasingly fierce market competition and the rapid change of external environment make cross-border cross-border technology sharing, resource integration and business cooperation become one of the most effective ways to achieve strategic goals Many countries, such as the United States, the European Union and Japan, regard the biotechnology industry as a strategic industry with priority in the 21st century GBI Health pointed out in the report of 2017 new drug review summary that in 2017, China's innovative drugs achieved blowout, the most in 10 years As an important biomedical market in the world, China's new drug R & D industry has given new vitality in the continuous positive innovation Local biotech and pharmaceutical companies have been actively adapting to the new policy of drug administration in the spring breeze of the policy At the same time, they are keen to seize the opportunity of global new drug R & D transformation, and actively integrate with the international community in new drug project approval, R & D strategy, R & D mode, capital operation, project transaction, etc in some advanced technologies and fields of new drug R & D, such as DNA coding compound library technology, car-t, etc cut a striking figure At the same time, many domestic and local enterprises, through holding hands with international partners, introduce the Chinese rights and interests of potential heavy drugs, and explore new shortcut of R & D and commercial cooperation Stones from other mountains can be used to attack jade With the support of Chengdu food and drug administration, Chengdu Economic and Information Commission, Chengdu Tianfu international biological city and other government departments, Chengdu pilot drug development Co., Ltd., Pfizer Asia innovation center, MSD research and development (China) Co., Ltd., Pfizer Asia innovation center, etc., in order to promote China's new drug creation and international integration, and promote the continuous enhancement of independent innovation capacity of national pharmaceutical industry Ltd., Johnson & Johnson Asia Pacific innovation center, GlaxoSmithKline and Shenzhen micro core Biotechnology Co., Ltd jointly held the 2018 International Summit Forum on frontier and practice of innovative drug discovery, and the 8th International Summit Forum on DNA coding compound library technology will be held at the same time (editor's note: the forum has moved to China for the first time The past seven sessions have been held in Boston, the United States and Zurich, Switzerland This year, it will be held in turn in the United States, Switzerland and Chengdu, China) The biomedical industry focuses on Chengdu, and the two international summits on new drug R & D are blooming at the same time In order to create a new international biomedical ecosystem and promote the cross-border flow of innovation "blood", top pharmaceutical wisdom is gathered With the theme of "innovation, pragmatism and cooperation" and the scale of 1200 +, this summit forum specially invited more than 60 heavyweight experts and scholars with rich experience in relevant fields, including Pfizer, Johnson & Johnson, MSD, Sanofi, Amgen, GSK, Roche, bringer, etc., to give keynote speeches Business executives and research elites with international business cooperation and drug R & D experience of famous pharmaceutical enterprises such as ingelham, Jiangsu Hengrui, aduro, and experts from famous universities and research institutions such as Scripps Research Institute, Jingtai technology, Purdue University, York University, Peking University, etc focus on analysis and policy analysis of biomedical Market at home and abroad, and study and judge smart medical industry New trends, hot discussion of new drug research and development targets, new technologies, sharing many domestic and foreign first-line new drug research and development examples Some registered participants rank in no order The conference aims to build an international biomedical ecosystem, a global information sharing platform for biomedical forward-looking information and cutting-edge ideas exchange and sharing, and a new drug R & D technology exchange and integration through various channels such as keynote speech, symposium, one on one partnering meeting system, flashtalk, exhibition stand display and academic wall newspaper exchange Innovation technology platform, at the same time, has become an international business platform for docking innovation resources and promoting cross-border business cooperation 01 one on one partnering meeting system precisely connects with high-efficiency talks 1 Face to face exchanges with experts from top universities and scientific research institutes to find new breakthrough points of the project Scripps Institute, University of Texas, Baylor School of medicine, Purdue University, York University, Johns Hopkins University, Swiss Federal Institute of technology and Tsinghua University, Peking University, Hong Kong University, Shanghai University, Shanghai Institute of medicine, etc 2 One to one talk with the executives of the world-famous biopharmaceutical companies to promote the implementation of project cooperation Johnson & Johnson, Pfizer, Sanofi, Roche, Novartis, MSD, GlaxoSmithKline, bringer Ingelheim, Lilly pharmaceutical, Novo Nordisk, Amgen, Eugene, humanwell pharmaceutical, China Resources pharmaceutical, Kanghong pharmaceutical, Zhengda Tianqing, Nanjing Shenghe, Beida pharmaceutical, aduro, Fosun Pharmaceutical, Jingxin pharmaceutical, North China pharmaceutical, Jiangsu Xiansheng, Jiangsu Hengrui, Sichuan Kelun, East Sunshine , Tianshili, xinlitai, Qilu pharmaceutical, etc 3 Negotiate with professional investment institutions on entrepreneurship projects and incubate every idea worthy of attention Sequoia Capital, Fidelity Investment, Bencao capital, tungstone fund, CDH investment, China new venture capital, etc Some well-known units that have joined the system: 02 flashtalk makes every innovation have its own voice car-t, accompanying diagnosis, AI and other emerging technologies, new drug research and development cases and other "mini" speeches one by one, causing thousands of guests in the main venue to communicate with each other and to collide with wisdom Here are some flashtalk projects 1 Speech theme: discovery of biological drugs based on antibody library and car-t library guest speaker: Liu Jianghai, general manager unit: Chengdu shengshijunlian Biotechnology Co., Ltd 2 Speech theme: significance of diagnosis in new drug development guest speaker: Zhang Yizhe, founder and Chairman: Zhejiang digital Biotechnology Co., Ltd 3 Speech theme: success rate of new drug research and development in 2018, Hot target, transaction trend analysis Speaker: Scott Yu, director of Greater China unit: informa Pharma intelligence 4 Speech topic: digital and artificial intelligence to help new drug development Speaker: Yang Hongfei, CEO unit: Hangzhou fairstone Technology Co., Ltd 5 Speech topic: research and development speaker of new anti-tumor drug eed inhibitor br554: Zou bin, general manager Setting: Shanghai Qingyu Pharmaceutical Technology Co., Ltd 6 Theme: discovery of anti hepatitis B candidate drugs based on biological diversity Speaker: Xu Min, Professor: Kunming University of science and technology in continuous update.. 03 exhibition stand (arranged by booth number) pharmaceutical intelligence network Shanghai medixi biomedical Co., Ltd Nanjing Kingsway Biotechnology Co., Ltd J & K bailingwei Huawei Pharmaceutical (Jiangsu) Co., Ltd Suzhou jinweizhi Biotechnology Co., Ltd aijiyan Technology (Shanghai) Co., Ltd Suzhou Jingyun Pharmaceutical Technology Co., Ltd Sandia Pharmaceutical Technology (Shanghai) Co., Ltd Beijing yingkerui innovative pharmaceutical research Co., Ltd Yidao Biotechnology Co., Ltd Chengdu shengshijunlian Biotechnology Co., Ltd Shimadzu enterprise management (China) Co., Ltd Beijing baiaozhi Information Technology Co., Ltd Dejin International Technology Co., Ltd Bruker Corporation Chongqing Lianqing Instrument Co., Ltd andI Biotechnology (Shanghai) Co., Ltd Illumina China applied for registration There is no registration fee for this meeting, and catering service is provided Please complete the online registration before October 15, 2018 Scanning the two-dimensional code above can complete the meeting registration agenda All trademarks, registered trademarks, brand names, logos and logos displayed in this article are owned by the corresponding obligees It is possible that the marks of TM and ® may be omitted in this paper If the obligee is not willing to display, please leave a message in the background in time to remove.